Research programme: cancer therapy - CEPTYRAlternative Names: CEPTYR 234; PTPx inhibitor; PTPxx; PTPy
Latest Information Update: 09 Jul 2007
At a glance
- Originator CEPTYR
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Jul 2004 Compounds from this research programme are available for licensing (http://www.ceptyr.com)
- 30 Jul 2003 Preclinical development for Cancer in USA (unspecified route)